Family-owned pharma company Rovi has a strong position in the heparin market in Europe. It has a ''risk-free'' agreement with Moderna to produce its COVID vaccine outside the US and a potential game-changing new long acting injectable product for schizophrenia (Doria) that could help group sales double by 2025 vs 2019 and EBITDA rise fourfold. We see limited regulatory and leverage risk.
Pharma business boosted by enoxaparin biosimilar
Low molecular weight heparins represent 46% of sales. Laun ....
20 Oct 2020
A new story begins beyond heparins
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A new story begins beyond heparins
- Published:
20 Oct 2020 -
Author:
Ruiz Francisco FR -
Pages:
51
Family-owned pharma company Rovi has a strong position in the heparin market in Europe. It has a ''risk-free'' agreement with Moderna to produce its COVID vaccine outside the US and a potential game-changing new long acting injectable product for schizophrenia (Doria) that could help group sales double by 2025 vs 2019 and EBITDA rise fourfold. We see limited regulatory and leverage risk.
Pharma business boosted by enoxaparin biosimilar
Low molecular weight heparins represent 46% of sales. Laun ....